drugset / Trial / NCT05854381
To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV
Phase 1
Completed
93 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
HIV Vaccine Trials Network · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity of VIR 1388 in adults in good health without HIV.
Timeline
- Start
- 2023-09-19
- Primary completion
- 2025-09-19
- Completion
- 2025-11-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VIR-1388 | Vaccine | 50000 unknown | Subcutaneous |
| Subject | VIR-1388 | Vaccine | 500000 unknown | Subcutaneous |
| Subject | VIR-1388 | Vaccine | 5e+06 unknown | Subcutaneous |